Statements (73)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
intravenous injection
|
| gptkbp:approves |
gptkb:2010
gptkb:FDA |
| gptkbp:chemical_formula |
C22 H28 Br N3 O5
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
second-line treatment
third-line treatment |
| gptkbp:contraindication |
hypersensitivity to eribulin
|
| gptkbp:developed_by |
gptkb:Eisai_Co.,_Ltd.
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| https://www.w3.org/2000/01/rdf-schema#label |
Halaven
|
| gptkbp:indication |
metastatic breast cancer
|
| gptkbp:ingredients |
gptkb:eribulin
|
| gptkbp:invention |
patented
|
| gptkbp:marketed_as |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:mechanism_of_action |
microtubule dynamics inhibitor
|
| gptkbp:pharmacokinetics |
highly protein-bound
induces apoptosis elimination half-life of 40 hours inhibits cancer cell growth |
| gptkbp:research_areas |
clinical trials
oncology pharmaceutical development |
| gptkbp:route_of_administration |
IV
|
| gptkbp:side_effect |
gptkb:anemia
dizziness fatigue headache muscle pain nausea weight loss abdominal pain cough fever vomiting seizures chest pain diarrhea hearing loss joint pain insomnia dehydration constipation chills shortness of breath neurological effects peripheral neuropathy skin rash hair loss thrombocytopenia infection risk hypotension visual disturbances neutropenia nail changes stomatitis peripheral edema cardiac toxicity liver function abnormalities fatigue syndrome kidney function abnormalities mucositis |
| gptkbp:storage |
room temperature
|
| gptkbp:trade |
gptkb:eribulin_mesylate
|
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:weight |
505.38 g/mol
|
| gptkbp:bfsParent |
gptkb:Eisai
|
| gptkbp:bfsLayer |
5
|